Osteodystrophy
Osteodystrophy refers to weakened, abnormal bone that develops when mineral metabolism goes wrong. The most common form is renal osteodystrophy, a complication of chronic kidney disease (CKD). When kidneys fail to activate vitamin D properly and can no longer filter phosphate, bones lose density, fracture more easily, and joints ache. CKD is a growing burden across South and Southeast Asia, making this condition increasingly relevant for patients in India, the Philippines, Thailand, and Indonesia.
Medicine used to treat Osteodystrophy
What drives the bone damage
Healthy kidneys convert vitamin D into its active form, calcitriol, which the body uses to absorb calcium and maintain bone matrix. In CKD, this conversion breaks down. Low active vitamin D triggers the parathyroid glands to overproduce parathyroid hormone (PTH), which draws calcium out of bones to keep blood levels stable. Over time, the bones thin and deform. Treatment centres on restoring the missing active vitamin D, which is why calcitriol is a cornerstone medicine for renal osteodystrophy and sits within the broader bone health therapeutic area.
Bone pain, skeletal deformity, and fractures from minor falls are red-flag symptoms that warrant prompt medical review, particularly in anyone with known kidney disease.